Literature DB >> 12629149

The role of CCL22 (MDC) for the recruitment of eosinophils during allergic pleurisy in mice.

Vanessa Pinho1, Sandra H Oliveira, Danielle G Souza, Denise Vasconcelos, Ana Letícia Alessandri, Nicholas W Lukacs, Mauro M Teixeira.   

Abstract

Eosinophils are important inflammatory cells in allergic diseases. In the present study, we have investigated the effects of CCL22 on the recruitment of eosinophils in vivo and in vitro. CCL22 induced a dose- and time-dependent recruitment of eosinophils into the pleural cavity of mice, and this was dependent on the release of platelet-activating factor (PAF) and subsequent generation of CCL11. However, in an allergic pleurisy model, an anti-CCL22 polyclonal antibody given during sensitization or before challenge had no significant effect on eosinophil recruitment. CCL22 did not induce eosinophil chemotaxis in vitro but was able to induce eosinophil degranulation in vitro and in vivo. In conclusion, we show that although exogenously added CCL22 may induce eosinophil migration in vivo via release of PAF and CCL11 (eotaxin), endogenous production of CCL22 does not drive eosinophil migration during allergic inflammation. However, CCL22 may be an important activator of eosinophils once these cells have migrated into tissue.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12629149     DOI: 10.1189/jlb.0502243

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  6 in total

1.  Ccl22/MDC, is a prostaglandin dependent pyrogen, acting in the anterior hypothalamus to induce hyperthermia via activation of brown adipose tissue.

Authors:  Olivia Osborn; Manuel Sanchez-Alavez; Jeffrey S Dubins; Alejandro Sanchez Gonzalez; Brad Morrison; John R Hadcock; Tamas Bartfai
Journal:  Cytokine       Date:  2010-12-21       Impact factor: 3.861

2.  Role of CCR4 ligands, CCL17 and CCL22, during Schistosoma mansoni egg-induced pulmonary granuloma formation in mice.

Authors:  Claudia Jakubzick; Haitao Wen; Akihiro Matsukawa; Maya Keller; Steven L Kunkel; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

3.  Oxaliplatin Treatment Alters Systemic Immune Responses.

Authors:  Vanesa Stojanovska; Monica Prakash; Rachel McQuade; Sarah Fraser; Vasso Apostolopoulos; Samy Sakkal; Kulmira Nurgali
Journal:  Biomed Res Int       Date:  2019-02-18       Impact factor: 3.411

Review 4.  Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications.

Authors:  Jean-Luc Galzi; Muriel Hachet-Haas; Dominique Bonnet; Francois Daubeuf; Sandra Lecat; Marcel Hibert; Jacques Haiech; Nelly Frossard
Journal:  Pharmacol Ther       Date:  2010-02-01       Impact factor: 12.310

5.  Elevated serum levels of macrophage-derived chemokine and thymus and activation-regulated chemokine in autistic children.

Authors:  Laila Yousef Al-Ayadhi; Gehan Ahmed Mostafa
Journal:  J Neuroinflammation       Date:  2013-06-19       Impact factor: 8.322

6.  Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon.

Authors:  Vanesa Stojanovska; Rachel M McQuade; Sarah Fraser; Monica Prakash; Shakuntla Gondalia; Rhian Stavely; Enzo Palombo; Vasso Apostolopoulos; Samy Sakkal; Kulmira Nurgali
Journal:  PLoS One       Date:  2018-06-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.